Cochrane · systematic review · CD015246
Intratympanic gentamicin for Ménière’s disease
Webster, KE, Galbraith, K, Lee, A, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
ENTAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 5 · 83.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Intratympanic gentamicin compared to no treatment/placebo for Ménière’s disease
Population: Ménière’s disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Improvement in vertigo frequency Intratympanic gentamicin vs no treatment/placebo | RR 33 [2.15, 507] | 1 study · 32 participants | Very low Downgraded: risk of bias |
Improvement in vertigo frequency Intratympanic gentamicin vs no treatment/placebo | RR 1.63 [0.98, 2.69] | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Vertigo (global score)Scale from: 0 (none) to 3 (severe) Intratympanic gentamicin vs no treatment/placebo | no estimate extracted | 1 study · 26 participants | Very low Downgraded: risk of bias, imprecision |
Vertigo (global score) Scale from: 0 (none) to 3 (severe) Intratympanic gentamicin vs no treatment/placebo | no estimate extracted | 1 study · 26 participants | Very low Downgraded: risk of bias, imprecision |
Vertigo (frequency) Intratympanic gentamicin vs no treatment/placebo | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Intratympanic gentamicin vs no treatment/placebo | no estimate extracted | NR | No studies |